Notable Insider Selling at Applied Materials Inc. (AMAT) and Costco Wholesale (COST), Plus Insider Moves at 3 Other Companies

Insiders at Low-Priced Intellectual Property Company Buy Shares Via Public Offering

Two different insiders at Inventergy Global Inc. (NASDAQ:INVT) purchased shares of the company this week through a public offering of shares and warrants. To start with, Board member Francis P. Barton purchased a new stake of 17,600 shares on Tuesday at a price of $1.00 each. The purchase also entitled Mr. Barton to warrants to purchase another 17,600 shares of common stock. More importantly, Chairman and CEO Joseph W. Beyers acquired 20,000 shares, plus warrants to purchase an additional 20,000 shares. After the recent purchase, the CEO currently holds an ownership stake of 600,231 shares of common stock.

The shares of the Silicon Valley intellectual property company took a hit when Inventergy announced plans to offer 6 million shares at $1.00 apiece, along with warrants to purchase up to another 6 million shares. The net proceeds from the offering, totaling around $5.30 million, will bring Inventergy Global Inc. (NASDAQ:INVT)’s stockholders’ equity above the Nasdaq requirement of $2.5 million. In fact, this offering was part of the company’s plan of compliance agreed to with Nasdaq. The IP investment and licensing company that assists technology-leading corporations attain greater value from their IP assets has seen the value of its shares drop by 53% since the start of the year.

Top-Tier Executive at Oncology Drug Development Company Purchases Shares

Two of the most well-informed and influential executives at Champions Oncology Inc. (NASDAQ:CSBR) purchased shares over the past several trading sessions. President Ronnie Morris snatched up 9,537 shares on Monday at a price of $1.66 each, lifting his overall holding to 1.03 million shares. Moreover, Chief Executive Officer Joel Ackerman bought 5,000 shares on Friday at $1.64 apiece and 3,202 shares on Thursday at prices that fell between $1.61 and $1.62 per share. After the recent transactions, the CEO currently owns 1.03 million shares.

The oncology drug development company that develops advanced technology solutions and products used in the development and use of oncology drugs has seen the value of its stock plummet by 52% this year. Champions Oncology Inc. (NASDAQ:CSBR)’s TumorGraft Technology Platform offers a novel approach to simulating the results of human clinical trials used in developing oncology drugs. As a result, the company’s platform facilitates drug discovery with much lower costs and increased speed of development. The company’s revenue for the three months ended July 31 came in at $3.67 million, up from $2.82 million recorded a year a prior. Hal Mintz’s Sabby Capital was the owner of around 547,000 shares of Champions Oncology Inc. (NASDAQ:CSBR) at the end of the second quarter.

The final page of this article will discuss the fresh insider selling witnessed at two other companies.